$AKBA
Akebia Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000156459015006991 Filed on August 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q4
Revenue $0.00 $84.00K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.900M $3.700M $3.500M
YoY Change 34.48% 60.87% 16.67%
% of Gross Profit
Research & Development $15.80M $7.182M $7.100M
YoY Change 137.67% 29.99% 121.88%
% of Gross Profit
Depreciation & Amortization $40.00K $32.00K $20.00K
YoY Change 203.19% 167.25%
% of Gross Profit
Operating Expenses $19.68M $10.89M $10.61M
YoY Change 105.32% 38.89% 71.05%
Operating Profit -$19.68M -$10.89M -$10.61M
YoY Change 105.32% 38.89% 71.05%
Interest Expense $100.0K $100.0K $100.0K
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net $203.0K $200.0K $237.0K
YoY Change -13.98% -9.91% -6.69%
Pretax Income -$19.50M -$10.70M -$10.40M
YoY Change 109.68% 40.79% 76.27%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.48M -$10.69M -$10.37M
YoY Change 108.33% 40.31% 74.37%
Net Earnings / Revenue -12725.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$677.1K -$402.3K -$522.6K
COMMON SHARES
Basic Shares Outstanding 28.88M 20.34M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.5M $114.0M $69.06M
YoY Change 104.54% 8.31% 111.85%
Cash & Equivalents $66.70M $76.25M $32.78M
Short-Term Investments $39.78M $37.79M $36.28M
Other Short-Term Assets $1.300M $2.100M $1.500M
YoY Change -7.14% 23.53% 114.29%
Inventory
Prepaid Expenses
Receivables $0.00 $48.00K $48.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $158.8M $155.0M $110.5M
YoY Change 32.55% 22.94% 230.47%
LONG-TERM ASSETS
Property, Plant & Equipment $500.0K $398.0K $210.0K
YoY Change 150.0% 119.85% 591.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $305.0K $305.0K
YoY Change 200.0% 143.33% 144.0%
Total Long-Term Assets $800.0K $703.0K $515.0K
YoY Change 100.0% 129.46% -58.27%
TOTAL ASSETS
Total Short-Term Assets $158.8M $155.0M $110.5M
Total Long-Term Assets $800.0K $703.0K $515.0K
Total Assets $159.6M $155.7M $111.0M
YoY Change 32.78% 23.19% 220.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $2.412M $2.021M
YoY Change 76.67% 62.08% 183.05%
Accrued Expenses $8.900M $3.491M $4.864M
YoY Change 154.29% 6.51% 52.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.20M $5.903M $6.885M
YoY Change 118.46% 23.76% 76.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $10.00K $32.00K
YoY Change -66.14% 300.0%
Total Long-Term Liabilities $0.00 $10.00K $32.00K
YoY Change -66.14% 300.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.20M $5.903M $6.885M
Total Long-Term Liabilities $0.00 $10.00K $32.00K
Total Liabilities $14.20M $5.913M $6.917M
YoY Change 115.15% 23.04% 76.91%
SHAREHOLDERS EQUITY
Retained Earnings -$122.1M -$100.7M
YoY Change 50.77% -20.77%
Common Stock $272.0M $205.0M
YoY Change 134652375.25%
Preferred Stock
YoY Change
Treasury Stock (at cost) $162.0K $162.0K
YoY Change 658.36%
Treasury Stock Shares $8.463K $8.463K
Shareholders Equity $145.4M $149.8M $104.1M
YoY Change
Total Liabilities & Shareholders Equity $159.6M $155.7M $111.0M
YoY Change 32.81% 23.19% 220.19%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q4
OPERATING ACTIVITIES
Net Income -$19.48M -$10.69M -$10.37M
YoY Change 108.33% 40.31% 74.37%
Depreciation, Depletion And Amortization $40.00K $32.00K $20.00K
YoY Change 203.19% 167.25%
Cash From Operating Activities -$9.040M -$12.11M -$9.200M
YoY Change 61.43% 81.56% 87.37%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$30.00K -$20.00K
YoY Change 175.0% 0.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities -$14.34M -$4.250M -$7.610M
YoY Change -64.11% -81.56% -534.86%
Cash From Investing Activities -$14.46M -$4.280M -$7.630M
YoY Change -63.85% -81.46% -538.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.95M 64.75M -50.00K
YoY Change -11725.0% -5587.29% -77.27%
NET CHANGE
Cash From Operating Activities -9.040M -12.11M -9.200M
Cash From Investing Activities -14.46M -4.280M -7.630M
Cash From Financing Activities 13.95M 64.75M -50.00K
Net Change In Cash -9.550M 48.36M -16.88M
YoY Change -79.11% -256.35% 397.94%
FREE CASH FLOW
Cash From Operating Activities -$9.040M -$12.11M -$9.200M
Capital Expenditures -$110.0K -$30.00K -$20.00K
Free Cash Flow -$8.930M -$12.08M -$9.180M
YoY Change 60.61% 81.93% 87.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Akebia Therapeutics, Inc.
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6885000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3707000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2315000
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
AKBA
dei Entity Central Index Key
EntityCentralIndexKey
0001517022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
398000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3491000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4864000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-27000
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28882530
CY2015Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
8463
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-987000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-27000
akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
104596000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
21000
akba Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
121000
akba Assets Acquired Under Capital Leases
AssetsAcquiredUnderCapitalLeases
12000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28882530
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
271998000
CY2015Q2 us-gaap Treasury Stock Value
TreasuryStockValue
162000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122057000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
149752000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155665000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110995000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28882530
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
76138000
CY2015Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
76541000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2125000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76248000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32780000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-56000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q2 us-gaap Liabilities
Liabilities
5913000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20370624
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100673000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
162000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204969000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
104078000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20370624
CY2014Q4 us-gaap Liabilities
Liabilities
6917000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
305000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2021000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
154962000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
305000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
110480000
CY2015Q2 us-gaap Assets
Assets
155665000
CY2014Q4 us-gaap Assets
Assets
110995000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2412000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7098000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6066000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
10889000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
7840000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26614671
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23340590
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21411000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19652056
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7626000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10708000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2296701
us-gaap Operating Expenses
OperatingExpenses
17749000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21785000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11683000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17749000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14687000
us-gaap Operating Expenses
OperatingExpenses
21785000
us-gaap Net Income Loss
NetIncomeLoss
-17315000
us-gaap Net Income Loss
NetIncomeLoss
-21384000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10987692
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.48
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17323000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-25000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
8463
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
610000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
950000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5903000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5525000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21384000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104215000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
104573000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
74179000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95394000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
227000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6745000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
24291000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17717000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
109000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20464000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
34790000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
35434000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-871000
akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
64624000
akba Assets Acquired Under Capital Leases
AssetsAcquiredUnderCapitalLeases
12000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7618000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7182000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10889000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7840000
CY2015Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
116000
CY2014Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
51000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
212000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
70000
CY2015Q2 us-gaap Reimbursement Revenue
ReimbursementRevenue
84000
CY2014Q2 us-gaap Reimbursement Revenue
ReimbursementRevenue
171000
us-gaap Reimbursement Revenue
ReimbursementRevenue
189000
us-gaap Reimbursement Revenue
ReimbursementRevenue
364000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-10689000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-7618000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
86900000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10689000
us-gaap Depreciation
Depreciation
50000
us-gaap Depreciation
Depreciation
20000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-271000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2223000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3889000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-21000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1603000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
30000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12677000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
76194000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1993078
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense, fair value of common stock and preferred stock and the Company&#8217;s other equity instruments (in periods prior to the IPO), accrued expenses, prepaid expenses and income taxes. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair market value of its common stock as determined by the Board of Directors contemporaneously at the date such grants were made, with input from management. Prior to the Company&#8217;s IPO in March&#160;2014, the fair value of common stock at the grant date was adjusted in connection with the Company&#8217;s retrospective fair value assessment for financial reporting purposes. Accordingly, the Board of Directors determined the estimated fair value of the Company&#8217;s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time and the likelihood of achieving a liquidity event, such as an IPO or sale of the Company.&nbsp;&nbsp;</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, investments and accounts receivable are the only financial instruments that potentially subject the Company to concentrations of credit risk. At June 30, 2015 and December 31, 2014, all of the Company&#8217;s cash was deposited in accounts at two principal financial institutions. The Company maintains its cash with high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. </p></div>
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
39000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
38756000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
261000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
101000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2460000
CY2015Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
263000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
76568000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2015Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
76248000
CY2015Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
152816000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37785000
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
86900000
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.75
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-02-27
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Revenues
Revenues
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
499000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
60000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
32780000
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
108974000
CY2014Q4 akba Cash Cash Equivalents And Short Term Investments Fair Value Disclosure
CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure
108918000
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
152789000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
108918000
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1707000
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
177000
CY2015Q2 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
60000
CY2014Q4 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
179000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
596000
CY2014Q1 us-gaap Severance Costs1
SeveranceCosts1
300000
us-gaap Payments For Restructuring
PaymentsForRestructuring
46000
CY2013Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P3Y
CY2013Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
6837
CY2013Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
31000
CY2013Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
31000
CY2013Q4 akba Lease Commencement Period
LeaseCommencementPeriod
2014-01
CY2013Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
125345
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8530
CY2014Q4 akba Lease Space Occupancy Date
LeaseSpaceOccupancyDate
2015-03-13
CY2014Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
45000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
32000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-12-31
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
100000
CY2015Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
125345
CY2014Q4 us-gaap Security Deposit
SecurityDeposit
179130
akba Capital Lease Term
CapitalLeaseTerm
P3Y
akba Capital Lease Commencement Date
CapitalLeaseCommencementDate
2014-02
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
460000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
936000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1396000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
4000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
8000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
5000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
1000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
18000
CY2015Q2 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
18000
CY2015Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
464000
CY2015Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
944000
CY2015Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
5000
CY2015Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1000
CY2015Q2 us-gaap Contractual Obligation
ContractualObligation
1414000
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2014Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
9200000
CY2014 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
4300000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3617179
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1095000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1444000
CY2015Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1993078
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2296704
CY2014Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
akba Defined Contribution Plan Employees Age To Be Eligible Under Plan
DefinedContributionPlanEmployeesAgeToBeEligibleUnderPlan
P21Y

Files In Submission

Name View Source Status
0001564590-15-006991-index-headers.html Edgar Link pending
0001564590-15-006991-index.html Edgar Link pending
0001564590-15-006991.txt Edgar Link pending
0001564590-15-006991-xbrl.zip Edgar Link pending
akba-10q_20150630.htm Edgar Link pending
akba-20150630.xml Edgar Link completed
akba-20150630.xsd Edgar Link pending
akba-20150630_cal.xml Edgar Link unprocessable
akba-20150630_def.xml Edgar Link unprocessable
akba-20150630_lab.xml Edgar Link unprocessable
akba-20150630_pre.xml Edgar Link unprocessable
akba-ex101_270.htm Edgar Link pending
akba-ex311_9.htm Edgar Link pending
akba-ex312_6.htm Edgar Link pending
akba-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending